UroToday and PRIMR Announce Strategic Partnership to Enhance Clinical Trial Awareness
By: David Grew MD MPH
By combining forces, the two companies aim to assist clinical trial principal investigators and sponsors in amplifying awareness of their studies, ultimately driving increased patient enrollment and engagement.
∗ ∗ ∗
[Reno, Nev.,, March 5, 2024] - UroToday - GU Oncology Today® brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology and PRIMR, the foremost oncology clinical trial patient education company, are thrilled to announce their strategic partnership aimed at revolutionizing clinical trial awareness and education.
This partnership brings together UroToday's extensive communications network, reaching both patients and providers, with PRIMR's hallmark simple doctor-created educational style. By combining forces, the two companies aim to assist clinical trial principal investigators and sponsors in amplifying awareness of their studies, ultimately driving increased patient enrollment and engagement.
UroToday boasts a massive global audience of urologists and healthcare professionals, providing unparalleled access to medical communities worldwide. PRIMR's expertise lies in crafting easily digestible educational content tailored to patients and healthcare providers, simplifying complex medical concepts and facilitating informed decision-making.
"We are excited to join forces with PRIMR to empower both patients and providers with valuable educational resources related to oncology clinical trials," said Gina Carithers, Founder and CEO of UroToday. "This partnership aligns with our mission to advance urological care through education and collaboration."
Through this collaboration, PRIMR will leverage UroToday's robust distribution channels to disseminate educational materials directly to patients and providers interested in genitourinary oncology clinical trials. This strategic approach aims to bridge the gap between patients and trial sponsors, facilitating informed participation and enhancing patient-centered care.
"We are delighted to partner with UroToday to expand the reach of our educational initiatives and support oncology clinical trial awareness," remarked David Grew MD MPH, founder of PRIMR. "Together, we will empower patients with knowledge and enable healthcare providers to make informed decisions regarding clinical trial referrals."
The partnership between UroToday and PRIMR represents a significant step forward in advancing patient education and enhancing clinical trial awareness within the oncology community. By combining their respective strengths, the two companies are poised to drive positive change and improve outcomes for patients and healthcare providers alike.
For more information about UroToday and PRIMR, visit respective websites or reach out to their dedicated teams.